Journal
ACS NANO
Volume 14, Issue 3, Pages 2847-2859Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.9b06168
Keywords
degradable carbon-silica nanocomposite; patient-derived xenograft tumor model; immunoadjuvant property; photothermal therapy; photodynamic therapy
Categories
Funding
- National Key Research and Development Program of China [2016YFA0201503]
- National Natural Science Foundation of China [21822802, 51772018, 51572271, 21304006, 51972343]
- Fundamental Research Funds for the Central Universities [buctrc201915, PYBZ1825, XK1802-8]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-1-007, 2018-I2M-1-002]
Ask authors/readers for more resources
Carbon nanomaterials have flourished for cancer therapy for decades. However, their practical applications on clinical bases still pose a challenge to address the dilemma of metabolism in vivo. In this study, an attempt is made to design a degradable carbon-silica nanocomposite (CSN) with immunoadjuvant property, which could undergo an enzyme-free degradation process into small particles (similar to 5 nm) and facilitate its clinical application. CSN harbors photothermal and photodynamic properties and as an immunoadjuvant would help to generate tumor-associated antigens and mature dendritic cells (DCs). Potent antitumor effects have been achieved in both 4T1 and patient-derived xenograft tumor models with tumor inhibition efficiencies of 93.2% and 92.5%, respectively. We believe that this strategy will benefit the possible clinical translation and carbon-silica-nanomaterial-based cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available